+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Osteoarthritis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018-2026

  • ID: 4851955
  • Report
  • November 2018
  • Region: Global
  • 185 pages
  • Transparency Market Research
1 of 2

Global Osteoarthritis Drugs Market: Overview

This report analyzes the current and future scenario of the global osteoarthritis drugs market for the period 2018 to 2026. Rise in geriatric population, prevalence of obesity, high unmet medical needs, and rich pipeline are likely to be major drivers of the global osteoarthritis drugs market during the forecast period.

The global osteoarthritis drugs market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on drug class, route of administration, distribution channel, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides market attractiveness analysis based on region and market share analysis in terms of key players, thereby presenting a thorough analysis of the overall competitive scenario in the global osteoarthritis drugs market.

Global Osteoarthritis Drugs Market: Key Segments

Based on drug class, the global osteoarthritis drugs market has been segmented into corticosteroids, NSAIDs & others, and viscosupplementation agents. The segments have been analyzed based on available drugs used during the treatment of osteoarthritis, and cost-effectiveness. In terms of route of administration, the global osteoarthritis drugs market has been classified into oral, parenteral, and topical. Based on distribution channel, the global osteoarthritis drugs market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. Market size and forecast for each of these segments have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year.

Global Osteoarthritis Drugs Market: Regional Outlook

In terms of region, the global osteoarthritis drugs market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). Market size and forecast for each of these regions and the mentioned countries have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in the Report

The report also profiles major players operating in the global osteoarthritis drugs market based on various attributes, such as, company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include Horizon Pharma plc, Pfizer Inc., Sanofi, Anika Therapeutics Inc., Ferring B.V., Bioventus Inc, Chugai Pharmaceutical Co. Limited, Alkem Laboratories, Flexion Therapeutics Inc., and Zimmer Biomet Holdings Inc.

The global osteoarthritis drugs market has been segmented as below:

  • Global Osteoarthritis Drugs Market, by Drug Class
    • Corticosteroids
    • NSAIDs & Others
    • Viscosupplementation Agents
  • Global Osteoarthritis Drugs Market, by Route Of Administration
    • Oral
    • Parenteral
    • Topical
  • Global Osteoarthritis Drugs Market, by Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Osteoarthritis Drugs Market, by Region
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • South Africa
      • GCC Countries
      • Rest of Middle East & Africa
Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Osteoarthritis Drugs Market

4. Market Overview
4.1. Overview
4.1.1. Market Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Osteoarthritis Drugs Market Analysis and Forecast, 2016-2026
4.4.1. Global Osteoarthritis Drugs Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1.Disease Prevalence & Incidence Rate globally with key countries
5.2.Regulatory Scenario by Region/globally
5.3.Pipeline Analysis

6. Global Osteoarthritis Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Global Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016-2026
6.3.1. Corticosteroids
6.3.2. NSAIDs & others
6.3.3. Viscosupplementation Agents
6.4. Global Osteoarthritis Drugs Market Attractiveness by Drug Class

7. Global Osteoarthritis Drugs Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Global Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016-2026
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Topical
7.4. Global Osteoarthritis Drugs Market Attractiveness, by Route of Administration

8. Global Osteoarthritis Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Global Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016-2026
8.3.1. Hospital pharmacies
8.3.2. Retail pharmacies
8.3.3. Online pharmacies
8.4. Global Osteoarthritis Drugs Market Attractiveness, by Distribution Channel

9. Global Osteoarthritis Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Osteoarthritis Drugs Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Osteoarthritis Drugs Market Attractiveness, by Region

10. North America Osteoarthritis Drugs Market Analysis and Forecast
10.1. Introduction
10.2. North America Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016-2026
10.2.1.Corticosteroids
10.2.2. NSAIDs & Others
10.2.3.Viscosupplementation agents
10.3. North America Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016-2026
10.3.1. Oral
10.3.2. Parenteral
10.3.3. Topical
10.4. North America Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016-2026
10.4.1. Hospital pharmacies
10.4.2. Retail pharmacies
10.4.3. Online pharmacies
10.5. North America Osteoarthritis Drugs Market Value Forecast, by Country, 2016-2026
10.5.1. US
10.5.2. Canada
10.6. North America Osteoarthritis Drugs Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country

11. Europe Osteoarthritis Drugs Market Analysis and Forecast
11.1.Introduction
11.2. Europe Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016-2026
11.2.1. Corticosteroids
11.2.2. NSAIDs & Others
11.2.3. Viscosupplementation agents
11.3. Europe Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016-2026
11.3.1. Oral
11.3.2. Parenteral
11.3.3. Topical
11.4. Europe Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016-2026
11.4.1. Hospital pharmacies
11.4.2. Retail pharmacies
11.4.3. Online pharmacies
11.5. Europe Osteoarthritis Drugs Market Value Forecast, by Country/Sub-region, 2016-2026
11.5.1. Germany
11.5.2. France
11.5.3. U.K.
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Europe Osteoarthritis Drugs Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region

12. Asia Pacific Osteoarthritis Drugs Market Analysis and Forecast
12.1.Introduction
12.2. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016-2026
12.2.1. Corticosteroids
12.2.2. NSAIDs & Others
12.2.3. Viscosupplementation agents
12.3. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016-2026
12.3.1. Oral
12.3.2. Parenteral
12.3.3. Topical
12.4. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016-2026
12.4.1. Hospital pharmacies
12.4.2. Retail pharmacies
12.4.3. Online pharmacies
12.5. Asia Pacific Osteoarthritis Drugs Market Value Forecast by Country/Sub-region, 2016-2026
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region

13. Latin America Osteoarthritis Drugs Market Analysis and Forecast
13.1.Introduction
13.2. Latin America Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016-2026
13.2.1. Corticosteroids
13.2.2. NSAIDs & Others
13.2.3. Viscosupplementation agents
13.3. Latin America Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016-2026
13.3.1. Oral
13.3.2. Parenteral
13.3.3. Topical
13.4. Latin America Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016-2026
13.4.1. Hospital pharmacies
13.4.2. Retail pharmacies
13.4.3. Online pharmacies
13.5. Latin America Osteoarthritis Drugs Market Value Forecast, by Country/Sub-region, 2016-2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Osteoarthritis Drugs Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region

14. Middle East & Africa Osteoarthritis Drugs Market Analysis and Forecast
14.1.Introduction
14.2. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016-2026
14.2.1. Corticosteroids
14.2.2. NSAIDs & Others
14.2.3. Viscosupplementation agents
14.3. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016-2026
14.3.1. Oral
14.3.2. Parenteral
14.3.3. Topical
14.4. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016-2026
14.4.1. Hospital pharmacies
14.4.2. Retail pharmacies
14.4.3. Online pharmacies
14.5. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Country/Sub-regions, 2016-2026
14.5.1. GCC Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country

15. Competition Landscape
15.1. Global Osteoarthritis Drugs Market Player - Competition Matrix (by Tier and Size of companies)
15.2. Global Osteoarthritis Drugs Market Share Analysis, by Company (2016)
15.3. Company Profiles
15.3.1. Horizon Pharma plc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Pfizer Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sanofi
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Anika Therapeutics, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Ferring B.V.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Bioventus, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Chugai Pharmaceutical Industries Limited
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Alkem Laboratories
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Flexion Therapeutics, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Zimmer Biomet Holdings, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll